Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial - Smith, JA; Kitt, MM; Morice, AH (Lancet Resp Med, 2020)
et al.